BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) appointed immunology expert, Cara Haymaker, to its scientific advisory board, effective immediately.
In addition, Dr. Bill Williams, president and CEO, has been selected to coordinate an upcoming special issue of the peer-reviewed journals, Frontiers in Pharmacology and Frontiers in Oncology, with the research topic of, “targeted immunotherapy for cancer.”
Dr. Haymaker is an assistant professor at department of translational molecular pathology, division of pathology/lab medicine at The University of Texas MD Anderson Cancer Center.
Her research has focused on tumor-infiltrating lymphocytes and their immunologic characteristics in solid tumors. She has authored 45 peer-reviewed original research articles.
In a statement, Dr. Williams said Dr. Haymaker brings expertise in a wide array of areas, including in immuno-oncology, cancer biomarkers, protein design, personalized diagnostics, and engineering of targeted immunotherapies, to help guide BriaCell in the development of potent, targeted immunotherapies for advanced breast cancer patients with limited therapeutic options.
